Allergic Rhinitis Management in Jaipur

What allergic rhinitis is and how it happens

Allergic rhinitis is a chronic, IgE-mediated type 2 inflammatory disease that affects both adults and children. It is an allergic disorder of the nose and eyes affecting about a fifth of the general population. In India, allergic rhinitis affects 20% to 30% of people, and 15% of those people go on to develop asthma.

The condition is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. Sensitisation to inhaled allergens starts in the first year of life; indoor allergen sensitisation comes before pollen sensitisation. The clinical manifestation of allergic rhinitis is influenced by both the early and late phases of the allergic reaction in the nose.

The early phase occurs within minutes of allergen exposure, when histamine, proteases, and cytokines are released, causing sneezing, runny nose, and itching. The late-phase response, which happens hours later, is characterised by nasal obstruction and hyperreactivity due to eosinophil and Th2 cell-predominant inflammation.

Recurrent symptoms, typically nasal congestion, frequently last because cytokines and mediators produced in the early stages result in a second cellular inflammatory reaction that lasts for 4 to 8 hours. Priming describes increased nasal responsiveness to an allergen with repeated exposure, and it can also be caused by air pollution.

The "one airway, one disease" approach demonstrates how allergic rhinitis is frequently linked to conjunctivitis and/or asthma. Allergic rhinitis has traditionally been classified as seasonal or perennial based on sensitivity to cyclic pollens or year-round allergens such as dust mites, animal dander, cockroaches, and moulds. Following the internationally prescribed ARIA guidelines, allergic nasal illness is now classified as mild or moderate-to-severe, intermittent or persistent.

Symptoms of allergic rhinitis and warning signs needing same-day care

Classic symptoms include:

• Sneezing
• Rhinorrhea (runny nose)
• Nasal congestion
• Itching of the nose and eyes
• Postnasal drip

Clear nasal secretions are frequently seen, along with enlarged turbinates and a typically pale and slack nasal mucosa. Allergic rhinitis often co-occurs with asthma and conjunctivitis. It can be associated with sleep disturbance, fatigue, irritability, depression, inability to concentrate at work or school, and work absenteeism, thus exerting an adverse impact on quality of life.

It reduces quality of life and school and work performance. It is a frequent reason for office visits in general practice.

Warning signs that need urgent care the same day include sudden severe difficulty breathing, swelling of the face or throat, wheezing that does not improve with your usual inhaler, or signs of a severe allergic reaction (anaphylaxis) such as widespread hives, dizziness, or collapse. These are not typical allergic rhinitis symptoms and require immediate medical attention.

Causes and who is at higher risk

Allergic rhinitis is caused by immunoglobulin E (IgE)-mediated reactions to inhaled allergens. The main stimulus to the development of noninjection routes was the problem of the safety of injected SIT. Sensitisation to inhaled allergens starts in the first year of life; indoor allergen sensitisation comes before pollen sensitisation.

In the second to fourth decades of life, allergic rhinitis is most common, after which it gradually declines. The signs of rhinitis commonly peak in the second, third, and fourth decades of life after beginning in early childhood.

Although there are genetic determinants of total IgE levels and specific allergen sensitisation, neither the kind of atopic illness nor specific sensitivities seems to be heritable as simple genetic traits.

The chance of developing allergic rhinitis was found to be correlated with polymorphisms of transcription factors GATA binding protein 3, trans-acting T-cell-specific transcription factor, and interleukin (IL)-13 in a cohort of children followed up to age 10. Risk factors include inhalant and occupational allergens, as well as genetic factors.

Due to underlying genetic and immunologic differences, some populations are more susceptible. Genes TSLP, GATA3, IL-4, IL-13, and IL-33, which control Th2 cell differentiation and IgE synthesis, have polymorphisms found by genome-wide association studies. Variants in IL1RL1 and HLA-DQ have also been linked to increased incidence of atopy and allergic airway inflammation.

Those who have a family history of atopic diseases including asthma, eczema, or allergic conjunctivitis exhibit a genetically primed immune response marked by increased Th2 polarisation and eosinophilia. Air pollution and microbiological exposure are environmental stressors that can cause epigenetic changes, such as changed DNA methylation, that affect immunological tolerance and disease manifestation.

Several comorbid disorders have been associated with allergic rhinitis and include asthma, sinusitis, otitis media, nasal polyposis, lower respiratory tract infection, and dental malocclusion.

How allergic rhinitis is diagnosed: examination and tests

The diagnosis of allergic rhinitis is based on the clinical history and, if needed, on skin tests or the presence of serum-specific IgE antibodies to allergens.

Clinicians should make the clinical diagnosis when patients present with a history and physical examination consistent with an allergic cause and one or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing. Findings consistent with an allergic cause include clear rhinorrhea, nasal congestion, pale discoloration of the nasal mucosa, and red and watery eyes.

The pale discoloration of the nasal mucosa is a clinical observation made by experts to aid in diagnosis. A definite diagnosis is made based on three symptoms (sneezing and nasal itch, rhinorrhea, and nasal congestion), patient history of allergen exposure, and critical clinical examination findings (clear rhinorrhea, pale discoloration of nasal mucosa, and watery and red eyes).

Medical history, physical examination, and, if necessary, nasal endoscopy are used to diagnose allergic rhinitis. In certain cases, testing for allergen-specific IgE (skin prick or serum-specific IgE) is also performed. Skin testing for seasonal and perennial aeroallergens is useful to distinguish non-allergic rhinitis from allergic rhinitis and to show if IgE antibodies are present or absent.

For almost a century, clinical skin prick testing (SPT) has been used to help diagnose atopic, IgE-mediated disorders. SPT has been proven to be a reliable and effective way to identify allergies. SPT enables the assessment of several allergens in a single session, with results available in 15 to 20 minutes.

The nasal allergen provocation test is a sensitive, specific, and reproducible method, but it takes a long time and requires expert personnel.

Clinicians should perform and interpret, or refer to a clinician who can perform and interpret, specific IgE (skin or blood) allergy testing for patients with a clinical diagnosis who do not respond to empiric treatment, or when the diagnosis is uncertain, or when knowledge of the specific causative allergen is needed to target therapy.

Clinicians should assess patients for, and document in the medical record, the presence of associated conditions such as asthma, atopic dermatitis, sleep-disordered breathing, conjunctivitis, rhinosinusitis, and otitis media. Routine sinonasal imaging must not be performed in patients presenting with symptoms consistent with allergic rhinitis. It may be considered in patients who do not respond to therapy.

Referral to an allergist/immunologist should be considered for patients with severe or refractory disease, uncertainty regarding clinically relevant allergens, consideration of allergen immunotherapy, or substantial impairment in quality of life. Referral to an otolaryngologist may be appropriate when structural abnormalities, chronic rhinosinusitis, nasal polyps, recurrent epistaxis, or other conditions requiring endoscopic evaluation or surgical management are suspected.

Non-surgical treatment options for allergic rhinitis and when surgery is advised

Management of allergic rhinitis is based on symptom severity, symptom frequency, allergen exposure, patient preferences, and the presence of comorbid conditions such as asthma. Treatment typically includes allergen avoidance when feasible, pharmacotherapy, and allergen immunotherapy for selected patients. Pharmacologic therapy is the mainstay of treatment for most patients, with intranasal corticosteroids serving as first-line therapy for persistent or moderate-to-severe disease.

Patients with intermittent symptoms are often adequately managed with second-generation oral or intranasal antihistamines. Intranasal corticosteroids are the most effective monotherapy for persistent or moderate-to-severe allergic rhinitis and are recommended as first-line treatment for most patients.

Second-generation antihistamines are used to treat mild allergic rhinitis and are generally preferred over first-generation agents because they provide similar efficacy with fewer sedating and anticholinergic adverse effects. First-generation antihistamines should generally be avoided, particularly in young children and older adults, because of their unfavorable adverse-effect profile.

For moderate-to-severe allergic rhinitis or symptoms inadequately controlled with monotherapy, combination treatment with an intranasal corticosteroid and intranasal antihistamine may provide greater symptom control than either agent alone. Fixed-dose combination intranasal sprays, such as azelastine/fluticasone and olopatadine/mometasone, are available.

Treatment response should be reassessed periodically, with escalation, de-escalation, or changes in therapy guided by symptom control, adherence, medication technique, adverse effects, and patient preferences. Patients with persistent symptoms despite optimised pharmacotherapy should be evaluated for adherence, alternative diagnoses, and candidacy for allergen immunotherapy.

Allergen immunotherapy (AIT) represents the only currently available treatment that targets the underlying pathophysiology, and it may have a disease-modifying effect. Either the subcutaneous (SCIT) or sublingual (SLIT) routes may be used. SCIT and SLIT are recommended for both seasonal and perennial allergic rhinitis for short-term benefit.

To achieve long-term efficacy, it is recommended that a minimum of 3 years of therapy is used. Clinicians should offer, or refer to a clinician who can offer, immunotherapy (sublingual or subcutaneous) for patients who have inadequate response to symptoms with pharmacologic therapy with or without environmental controls.

Sublingual immunotherapy (SLIT) is an effective alternative for selected patients and is available for specific allergens, including certain grass pollens, ragweed pollen, and house dust mites. SLIT is generally most appropriate for patients with clinically relevant sensitisation to allergens covered by currently available products. It may be less suitable for patients with polysensitisation requiring treatment for multiple unrelated allergens.

Subcutaneous immunotherapy (SCIT) has been shown to reduce allergic rhinitis symptoms and medication requirements and may provide sustained clinical benefit after treatment is completed. Therapy is typically administered over 3 to 5 years and should be performed by appropriately trained clinicians because systemic allergic reactions, including anaphylaxis, may occur.

Environmental control measures should target clinically relevant allergens identified through the patient's history and, when indicated, allergy testing. Broad or indiscriminate allergen avoidance is generally not recommended. For seasonal allergens, limiting outdoor exposure during periods of high pollen counts, keeping windows closed, using air conditioning when appropriate, and showering after outdoor activities may help reduce allergen exposure.

For indoor allergens, strategies should be individualised according to the identified trigger. Dust mite exposure may be reduced by using a comprehensive, multicomponent approach, such as allergen-impermeable mattress and pillow covers, washing bedding regularly in hot water, and maintaining low indoor humidity, as single isolated interventions are unlikely to yield substantial clinical benefit.

Mold exposure may be reduced by controlling indoor moisture, and pet avoidance remains the most effective strategy for animal allergy, although limiting pet access to bedrooms and using high-efficiency particulate air (HEPA) filtration may provide some benefit when removal is not feasible. Patients with occupational allergy should minimise exposure whenever possible or use appropriate workplace protective measures.

Avoidance of nonspecific irritants, including tobacco smoke, air pollution, strong odours, and rapid temperature changes, may also improve symptoms in susceptible individuals. Smoking cessation and avoidance of secondhand smoke and other airborne irritants are recommended because these exposures may worsen rhinitis symptoms.

Adherence to prescribed pharmacotherapy before and during anticipated allergen exposure, particularly during seasonal pollen periods, may help prevent symptom exacerbations. Surgery is not a treatment for the underlying allergic disease but may be indicated for associated structural abnormalities or comorbid conditions, including chronic rhinosinusitis, severe septal deviation, inferior turbinate hypertrophy, nasal polyps, or other anatomic causes of persistent nasal obstruction.

Clinicians may offer, or refer to a surgeon who can offer, inferior turbinate reduction in patients with allergic rhinitis with nasal airway obstruction and enlarged inferior turbinates who have failed medical management.

Preparing for Allergic Rhinitis Management

Allergic rhinitis management at Jaipur Hospital is an outpatient process. You do not need to fast or stay in hospital. Before your first visit, note down when your symptoms are worst, what seems to trigger them, and any medicines you have already tried.

Bring a list of current medicines, including any eye drops or skin creams, so your doctor can check for interactions. If you have had previous allergy tests or blood reports, carry those as well. Your surgeon may ask you to stop antihistamines for a few days before skin prick testing, because they can hide the reaction.

You will be told exactly which medicines to pause and for how long. No special diet or bowel preparation is needed. Wear comfortable clothing and bring an attendant if you wish, though most patients manage the visit on their own.

How Allergic Rhinitis Management Is Done

Treatment is tailored to your symptom pattern, severity, and the allergens identified on testing. The main options are:

• Intranasal corticosteroids: a daily spray that reduces inflammation in the nasal lining. This is first-line treatment for persistent or moderate-to-severe symptoms.
• Antihistamines: oral tablets or nasal sprays that block histamine. Second-generation oral antihistamines are preferred because they cause less drowsiness. Intranasal antihistamines work faster and have fewer systemic effects.
• Sublingual immunotherapy (SLIT): drops or tablets placed under the tongue daily. SLIT is used for specific allergens such as grass pollen, ragweed, and house dust mite. It is generally most appropriate when you are sensitised to allergens covered by available products.
• Subcutaneous immunotherapy (SCIT): allergy shots given under the skin. The build-up phase involves weekly or twice-weekly injections for up to six months, followed by a maintenance phase of monthly injections for three to five years.

Your surgeon will advise which option suits you. On the day of a SCIT visit, you receive the injection in the clinic and wait about 30 minutes for observation. SLIT doses are taken at home after the first dose is given under medical supervision. Intranasal sprays and oral medicines are started at home with instructions on correct technique. Saline nasal irrigation may be added to wash out allergens and mucus.

Risks and Possible Complications of Allergic Rhinitis Management

Intranasal corticosteroids are well tolerated. Newer second-generation sprays have very low systemic absorption, so systemic side effects are uncommon. Nasal irritation, dryness, or mild bleeding can occur; using the correct spray technique reduces this. Oral antihistamines may cause mild drowsiness, dry mouth, or headache. First-generation antihistamines are avoided because of stronger sedation and anticholinergic effects.

Intranasal decongestant sprays must not be used for more than three to five days, as they can cause rebound congestion (rhinitis medicamentosa) and damage the nasal lining.

For SCIT, redness, warmth, itching, or swelling at the injection site are common. Systemic reactions such as hives, itching elsewhere, or trouble breathing are less common. Anaphylaxis is rare but possible, which is why shots are given in a setting with emergency care available. You must report any delayed reaction within 24 hours.

In one study, bronchospasm occurred in three patients and was linked to incorrect technique. Beta-blockers and ACE inhibitors can increase the risk of severe reactions or make them harder to treat. SLIT commonly causes local mouth itching or throat irritation; severe systemic reactions are very rare. Montelukast carries a boxed warning for neuropsychiatric effects and is reserved for selected patients. Short courses of oral steroids are used only for severe flare-ups.

Recovery and Aftercare for Allergic Rhinitis Management

There is no surgical recovery. Symptom control with intranasal corticosteroids and antihistamines usually begins within two to four weeks. You will be shown how to aim the spray away from the nasal septum to reduce bleeding. Saline rinses can be used before the steroid spray to clear mucus.

For SCIT, you stay in the clinic for about 30 minutes after each shot. Local reactions at the injection site settle within a few hours. If you notice increasing swelling, hives, breathing difficulty, or dizziness after leaving, return to the emergency department or call the hospital.

For SLIT, the first dose is taken under supervision; after that you continue daily at home. Keep a symptom diary and note any side effects. Follow-up visits are scheduled to check response, adjust doses, and review inhaler or spray technique. If symptoms persist despite optimised pharmacotherapy, your doctor will reassess the diagnosis, check adherence, and discuss immunotherapy candidacy. Smoking cessation and avoiding second-hand smoke improve outcomes. Environmental controls targeted to your specific allergens help reduce exposure.

Results of Allergic Rhinitis Management

In studies, intranasal corticosteroids are the most effective monotherapy for persistent or moderate-to-severe allergic rhinitis and improve nasal and eye symptoms as well as sleep quality. Combination therapy with an intranasal corticosteroid and intranasal antihistamine gives greater symptom control than either alone for moderate-to-severe disease. Fixed-dose combination sprays are available.

Allergen immunotherapy is the only disease-modifying treatment. In appropriately selected patients with confirmed IgE-mediated disease, immunotherapy reduces symptoms, decreases medication use, and can modify the long-term course of allergic disease. SCIT has shown sustained clinical benefit after treatment ends. SLIT is effective for specific allergens such as grass pollen, ragweed, and house dust mite.

The strongest evidence for long-term benefit is documented for grass allergen immunotherapy, especially tablets, where benefit persists after stopping. A minimum of three years of therapy is recommended for long-term efficacy. In one follow-up study, clinical efficacy was not maintained after discontinuation of local nasal immunotherapy, suggesting a pre-seasonal course may be needed each year.

However, a prospective observational study documented three to five years of lasting efficacy in some patients after stopping. Experts do not know exactly how long allergy shots work after you stop; some people remain symptom-free while others see allergies return within a few years. Immunotherapy may also prevent children with allergic rhinitis from developing asthma. Appropriate treatment improves quality of life, school and work productivity.

Cost and Insurance for Allergic Rhinitis Management in Jaipur

The typical yearly cost for medical management ranges from ₹2,000 to ₹15,000. A full course of immunotherapy (three to five years) typically costs ₹50,000 to ₹1,00,000. The final amount depends on the type of immunotherapy (SLIT or SCIT), the number of allergens treated, the brand of extracts or sprays used, and how long you need treatment.

Medical costs for allergic rhinitis are large, and avoidable costs from lost work productivity are even larger. LNIT avoids injection costs and loss of time because it is self-administered at home.

Jaipur Hospital accepts RGHS, MAA Yojana, CGHS, and a panel of private insurers and TPAs. Coverage for immunotherapy varies by scheme and policy; some plans cover the extracts and administration, others only cover consultations and medicines. Ask your insurer what is included under allergy treatment. The hospital's insurance desk can help verify benefits and process claims.

No advance deposit is required for OPD visits. You pay for medicines at the in-house pharmacy and for each immunotherapy visit as per the schedule.